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Knowledge  of  antibody  structure  is  now  sufficient  to  allow  investigation  of 
problems  of  biological  function  relative  to  structural  parameters.  One  such 
structure-function relationship that can be approached is the molecular basis for 
complement  (C)  activation  by  immunoglobulins.  On  the  basis  of  structural 
studies it has been proposed that the homology regions of immunoglobulins are 
arranged  in  a  series  of  compact  domains,  with  each  domain  mediating  a 
biological function (1). In line with this hypothesis it has been suggested that the 
C~,2 domain may play a role in C fixation by IgG (2, 3). In 1971 Augener et al. by 
use of active C1 (CT) fixation assay showed that the 7S subunit of IgM could bind 
CT  (4).  Plaut  et  al.  subsequently  demonstrated  that  the  (Fc)stt  and  Fctt 
fragments of IgM were capable of fixing C (5). We have investigated the relative 
capacity  of small  molecular  weight  fragments  of a  human  WaldenstrSm  IgM 
protein  (Dau)  to  bind  the  first  component  of C  and  are  thus  able  to  present 
evidence for the localization of this function to a  24 amino acid sequence. 
Materials and Methods 
Preparation of IgM and Its Subfragments.  IgM was isolated from the plasma of a patient (Dau) 
with Waldenstr6m's macroglobulinemia as previously described (6). (Fc)stt and FabtL fragments were 
prepared using trypsin digestion at 60°C (6). After separation of (Fc)5# and Fabtt on Sephadex G-200 
in  1%  NH4HCOs,  pH  8,  the  (Fc)stt was  further purified  on  Bio-Gel  A-15 (Bio-Rad Laboratories, 
Richmond,  Calif.).  Cyanogen  bromide  (CNBr)  cleavage  of  (Fc)~tz  and  Fabu  was  performed  as 
described by Zikan and Bennett (7). Dau Fc~ is composed of four CNBr fragments (7), designated 
CNBr 5 through CNBr 8 (Fig. 1). After CNBr cleavage the smaller fragments, CNBr 6 and CNBr 8, 
were removed by gel filtration (7). The disulfide bonds in the pentameric CNBr 5 plus 7 fragment 
were then gently cleaved (either by partial oxidative sulfitolysis  [8] or using 0.01 M  dithiothreitol 
followed by alkylation with iodoacetamide) and the sample was applied to a Sephadex G-150 column 
in 5 M  guanidine-HC1 to obtain CNBr 5 dimers and monomers which were free of CNBr 7, as shown 
by polyacrylamide disc electrophoresis in sodium dodecyl sulfate. 
In addition, 33,000 mol wt Fctt fragments were prepared by reducing Fcstt with 0,05 M  cysteine. 
The limited tryptic cleavage method of Hester and Schrohenloher (9) was used to release from the Fct~ 
fragments a  homogeneous 6,800 mol wt fragment. This fragment was designated the C H4 fragment, 
since  a  comparison  of  its  amino  acid  composition  and  partial  sequence  as  determined  in  the 
sequenceP with that published by Putnam et al. (10) for the IgM, Ou, revealed that it was composed 
of the Cu4 domain of the FctL minus two tryptic peptides in the center of the loop (residues 468-491 
and 515-550 according to the numbering of Ou). Relative to Dau CNBr fragments, C ~4 consisted of 
the carboxy-terminal 22 residues of CNBr 5 and the first two residues of CNBr 6 disulfide bonded to 
36 residues of CNBr 7. 
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FIG.  1.  Fragmentation of human IgM. Flow sheet summarizing the scheme used for isolation 
of the fragments tested for CT-fixing ability. The site of specific cleavage into Fab and (Fc)~u 
fragments by trypsin digestion at 60°C is shown, and the four homology regions of the g-chain 
(C/al-C~4)  are  identified.  Cyanogen  bromide  cleaves  the  (Fc)s~  into  four  fragments, 
designated  CNBr  5  through  CNBr  8.  Limited  tryptic  cleavage  of Fcg  produces  the  C H4 
fragment which  consists  of the COOH-terminal segment of CNBr 5 disulfide bonded  to a 
fragment from the center of CNBr 7. 
CT-Binding Assay.  The C-fixing ability of Dau IgM and its fragments was tested by a modified 
C]- fixation assay (4). The buffer utilized throughout the assay was dextrose-gelatin-veronal buffer of 
relative salt concentration 0.065 containing optimum amounts of Ca ++ and Mg  ÷÷ (11). An amount of 
functionally pure human C] sufficient to yield 63% lysis was incubated with serial dilutions of the test 
fragments or with buffer as a control for 10 min at 30°C. EAC4 (sheep erythrocytes [E] sensitized with 
rabbit antibody  [A] to E to which C components have been added)  (1.5 ×  108/ml) were then added 
and incubation was allowed  to proceed  for an additional  10 rain.  The resulting EAC1,4 cells were 
washed twice to remove unbound CT, and resuspended in the same buffer.  An excess of functionally 
pure  C2 (11) was then added,  followed by an excess  of C3-9 (guinea  pig C diluted 1:50 in 0.01 M 
EDTA buffer which supplies  an excess of the late-acting components)  and the degree of lysis deter- 
mined spectrophotometrically at 412 me. Appropriate controls  were included for each experiment 
(11). The amount of C1 fixed by an individual sample was calculated by subtracting the observed z 
value  [-  In (1  -  y),  where y  =  percent hemolysis],  where z represents the average  number of C]" 
molecules per cell, from the buffer control  z value (11). 
Results 
ACT fixation plot for Dau IgM and its CH4 fragment is shown in Fig. 2. 50% of the 
available C]" was fixed by 1.5 gg of intact IgM whereas 46 ~,g of the CH4 fragment 
were  required  to  fix  an  equivalent  amount  of  C]'.  The  amounts  of the  other 
fragments  of  IgM  which  were  needed  to  bind  50%  of  the  available  CT  are 
summarized  in  Table  I.  Whereas  only  1.5 ~g of Dau IgM were required to bind 
half of the available CT, to our surprise  up to 2,000 l*g of (Fc)5~,  which was the HURST  ET AL,  BRIEF DEFINITIVE REPORT  1119 
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FIG. 2.  Fixation  of human C1 by Dau IgM and its C.4 fragment. An amount of CT sufficient 
to produce 63% lysis of the cells in the absence of test material was used. After incubation the 
amount of unbound CT was determined and expressed as a percentage of that found when no 
test material was added during the incubation. 
TABLE I 
C7 Fixation by Dau IgM and Its Fragments 
Test material  Molecular weight*  Amount  S 
daltons  #g 
Dau IgM  840,000  1.5 
Fcs#  340,000  > 2,000 
Fcu  34,000  40 
Fab  48,000  > 2,750 
Reduced Fab  Unfractionated  > 1,575 
(CNBr 5) ~  40,000  20 
Fabc NB~  Unfractionated  > 1,125 
C ~4 Fragment  6,800  46 
* Data on the molecular weights of Dau IgM and its fragments were deter- 
mined as published [i.e., Fcst~, Fctt, and Fab (6). (CNBr 5)2 (7), and C.4 
Fragment ]. 1 
S Amount required to bind 50% of the available CT. 
highest amount tested, did not bind CT. However, if the assay were run such that 
whole human serum was incubated with the fragment (i.e.,  CHs0 fixation assay), 
there was C consumption as indicated by a  drop from 160 CHso U to 95 CHs0 U. 
This is in agreement with the data published by Plaut et al. (5) for the (Fc)stt of 
another  human  monoclonal  IgM  (Dis).  As  the  latter  assay  measures  total 
hemolytic  activity  (11),  it  might  be  that  (Fc)su  activates  the  late-acting  C 
components  and  very  little,  if any,  CT  is  actually  fixed.  Partial  reduction  of 
(Fc)su  provided  Fctt  fragments  which  were  effective  in  binding  CT.  Controls, 
consisting  of Fab#  and  partially  reduced  Fabtt,  did  not  bind  CT even  at  high 
concentrations. The 40,000 mol wt dimer of CNBr 5, which contains the Ctt3 and 
a  portion of the Ctt4 domain, was found to bind CT effectively (only 20 ttg being 
required).  In  contrast,  the  control  CNBr  digest  of Fabtt  was  not  capable  of 1120  HURST  ET  AL.  BRIEF  DEFINITIVE  REPORT 
binding CT. Finally, 46 ttg of the 6,800 mol wt C H4 fragment were needed to bind 
50% of the available C1. Sedimentation velocity analysis of this fragment in the 
analytical  ultracentrifuge  in the buffer used for the  CT fixation  assay failed to 
reveal observable aggregation.  In view of this,  it is remarkable that on a  molar 
basis the 60 residue C ~4 fragment is one-sixth as efficient as the Fcu fragment. 
Discussion 
The  only primary  structure  common to the  two smallest  CT-fixing fragments, 
CH4 and CNBr 5,  is the 24 residues on the amino-terminal  side of the disulfide 
loop making up the Ctt4 domain  (residues 468-491 in IgM Ou  [10]).  These data 
lead  us  to  suggest  that  this  portion  of the  Fctt  is responsible  for CT binding. 
However, the possibility that the CT-binding site in the intact molecule may also 
involve other  regions  of the  Fct+ is not necessarily ruled  out.  In  this  regard  it 
would be particularly interesting to test the CT-fixing ability of the Ctt3 domain 
when a  method for isolating  it is found.  It should be noted  that  the 24 residue 
sequence common  to  CH4 and  CNBr 5 has  the  highest  degree of homology to 
human  /~2-microglobulin  of any  in  the  terminal  domain,  having  8  out  of 24 
identities and a total of 14 out of 24 conservative replacements (see Putnam et al. 
[10] and Peterson et al.  [12] for comparative sequences). The relevance of this is 
pointed out by the fact that Painter et al. (13) have shown that/~2-microglobulin 
fixes CT with high efficiency. On the other hand,  a similar sequence comparison 
to the IgG domains (14)  reveals that the 24 residues of CH4 have a higher degree 
of homology to  C~3  than  to  the  C~,2  domain  which  has  been suggested to be 
responsible  for  C  activation  on  the  basis  of data  accumulated  using  the  CHs0 
assay  (2,  3).  Specifically,  there  are  11  out  of 24  identities  and  4  conservative 
replacements between these 24 residues of the C H4 fragment and the analogous 
24  residues  in  C~3,  compared  to  6  out  of  24  identities  and  3  conservative 
replacements between these 24 residues in C H4 and C~,2. In view of this and of our 
data  indicating  CHso but not  CT fixation  by (Fc)5#  it  would be of interest  to 
compare the CT-fixing ability of Ct+4 with that of C'r2 and C~r3. 
Summary 
An insight into the structural features of human IgM that are responsible for its 
capacity to bind the first component of complement  (C)  has been obtained by 
examining the ability of IgM subfragments to bind active C1 (C1). The smallest 
two fragments found to bind C]" were the major CNBr fragment of the Fc portion 
of IgM  and  the  C H4  fragment  of the  carboxy-terminal  domain.  The  smallest 
fragment  which  fixes  C]" has  a  disaggregated  mol  wt  of 6,800,  consists  of 60 
residues, and contains no carbohydrate.  Structural considerations and sequence 
overlaps suggest that the amino-terminal  side of the CH4 domain (24 amino acid 
residues)  might  be responsible for fixing C]'. 
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